首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 基因疗法

市场调查报告书

商品编码

1983360

血友病基因治疗市场：依血友病类型及地区划分

Hemophilia Gene Therapy Market, By Hemophilia Type (Hemophilia A, Hemophilia B), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

出版日期: 2026年02月13日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3个工作天内

价格

简介目录

据估计，2026年血友病基因治疗市场规模为14.08亿美元，预计2033年将达到176.84亿美元。预计2026年至2033年，该市场将以43.6%的复合年增长率成长。

分析范围		分析详情
基准年	2025	市场规模（2026 年）	14.08亿美元
效能数据	2020-2024	预测期	2026-2033
预测期（2026-2033 年）复合年增长率	43.60%	预计金额（2033 年）	176.84亿美元

血友病是一种遗传性出血性疾病，其特征是体内凝血因子缺乏或水平过低。约有13种凝血因子与血小板协同作用，启动凝血过程。血友病分为三种：A型、B型和C型。 AA型血友病最为常见，由凝血因子VIII缺乏所引起。 BB型血友病由凝血因子IX缺乏所引起，C型血友病由凝血因子XI缺乏所引起。目前的治疗方法无法治癒血友病，只能缓解肌肉和关节自发性出血以及颅内出血风险增加等症状。这些治疗方法仅能维持一天的疗效，而且费用昂贵。与传统的凝血因子替代疗法相比，基因疗法有望透过纠正患者体内编码凝血因子 VIII 或 IX 的缺陷基因序列（F8 或 F9 基因）来为血友病提供持久的治癒。

在这种治疗方法中，重组腺结合病毒最常用于将经过密码子优化的凝血因子（VIII 或 IX）基因递送至血友病患者体内。该基因透过删除特定片段进行缩短，以确保编码序列能够被病毒载体正确整合。研究观察到基因表现量呈现剂量依赖性，这意味着随着基因治疗剂量的增加，凝血因子的基因表现也会升高。

市场动态

美国食品药物管理局（FDA）等监管机构透过授予「突破性疗法认定」来支持基因治疗产品的研发，该认定适用于正在进行临床实验的基因疗法。例如，2017年，美国FDA授予baroctocogene roxaparvovec“突破性疗法认定”，这是一种使用5型腺结合病毒（AAV5）的VIII因子载体，旨在恢復A型血友病患者的血浆VIII因子水平。

本报告的主要特点

本报告对全球血友病基因治疗市场进行了详细分析，包括预测期（2026-2033 年）的市场规模和复合年增长率，以 2025 年为基准年。
此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本节根据以下参数介绍全球血友病基因治疗市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
《全球血友病基因治疗市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过分析全球血友病基因治疗市场中使用的各种策略矩阵来促进决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 北非
- 中非
- 南非

第六章竞争情势

市占率分析
公司简介
- BioMarin Pharmaceuticals, Inc.
- Spark Therapeutics
- Pfizer, Inc.
- UniQure NV
- Ultragenyx Pharmaceutical
- Shire PLC
- Sangamo Therapeutics, Inc
- Freeline Therapeutics

第七章

参考
分析方法

简介目录

Product Code: CMI2480

Hemophilia Gene Therapy Market is estimated to be valued at USD 1,408 Mn in 2026 and is expected to reach USD 17,684 Mn by 2033, growing at a compound annual growth rate (CAGR) of 43.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,408 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	43.60%	2033 Value Projection:	USD 17,684 Mn

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patient's body.

In this therapy, recombinant Adeno - associated virus is most commonly utilized to deliver a codon optimized version of the clotting factors genes (VIII or IX) to patients affected by hemophilia. This gene is shortened by deleting a discrete portion of the gene to better fit the coding sequence into the viral vector. There is dose dependent gene expression level observed which means genetic expression for clotting factor increases with increased dose of gene therapy.

Market Dynamics

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are supporting the product development for gene therapy by allotting breakthrough designation status to investigational gene therapy. For instance, in 2017, the U.S. FDA granted breakthrough therapy designation to valoctocogene roxaparvovec, which is an Adeno -associated virus 5 factor VIII vector designed to restore factor VIII plasma concentrations in patients with hemophilia A.

Key features of the study

This report provides an in-depth analysis of the global hemophilia gene therapy market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemophilia gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire, Sangamo Therapeutics, Inc., and Freeline Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia gene therapy market

Market Segmentation

Hemophilia Type Insights (Revenue, USD Mn, 2026 - 2033)
- Hemophilia A
- Hemophilia B
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- BioMarin Pharmaceuticals, Inc.
- Spark Therapeutics
- Pfizer, Inc.
- UniQure NV
- Ultragenyx Pharmaceutical
- Shire
- Sangamo Therapeutics Inc.
- Freeline Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Hemophilia Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Primary Research Respondents View About Market
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
PEST Analysis
Epidemiological Data

4. Global Hemophilia Gene Therapy Market, By Hemophilia Type, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hemophilia A
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hemophilia B
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Hemophilia Gene Therapy Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Hemophilia Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

6. Competitive Landscape

Market Share Analysis
Company Profiles
- BioMarin Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Spark Therapeutics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- UniQure NV
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Ultragenyx Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Shire PLC
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Sangamo Therapeutics, Inc
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Freeline Therapeutics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
  - Analyst Views

7. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

血友病基因治疗市场：依血友病类型及地区划分

Hemophilia Gene Therapy Market, By Hemophilia Type (Hemophilia A, Hemophilia B), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

市场动态